Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
All >

Deals > A Fine Selection by [iito]

[ # 12 & 35 ]
Find below a fine selection of interesting & curious, important & meaningless deals by [iito] Business Intelligence
|

Total search results: 354 | Ordered by Date (descending)
1 2 3 4  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF 2019-02-08
Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical 2019-01-31
Dewpoint Therapeutics–SEVERAL: investment, 201901 financing round Series A $60m led by Polaris Partners 2019-01-30
MAB Discovery–BioNTech: investment, 201901–201903 acquisition €na of Antibody Generation Unit of MAB Discovery by BioNTech 2019-01-23
CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR 2019-01-22
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share 2019-01-07
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years 2019-01-01
Mestrelab Research–Bruker Corp: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership 2018-12-13
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
Argen-X–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC 2018-12-03
JnJ–Argen-X: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen 2018-11-20
Omeicos–SEVERAL: investment, 201811 financing round Series C €17m led by new investor Forbion 2018-11-02
Endocyte–Novartis: investment, 201810– acquisition $2.1b in cash of Endocyte by Novartis ANNOUNCED 2018-10-18
LaVision BioTec–Miltenyi Biotec: investment, 201810 acquisition of LaVision BioTec GmbH by Miltenyi 2018-10-12
Gotham Therapeutics–SEVERAL: investment, 201810 financing round Series A $54m co-led by Versant Ventures + Forbion + SR One 2018-10-10
Sphingotec–SEVERAL: investment, 201810 financing round €20m co-led by HBM + Wellington Partners 2018-10-08
Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics 2018-09-28
CRISPR Therapeutics–SEVERAL: investment, 201809 public offering $200m net $185.7m with 4.21m common shares at $46.5/share 2018-09-19
Roche–Affimed: antibody cancer drug, 201808– collab $96m ufpront + $5b milestones + royalties using ROCK platform to develop ABs with Genentech 2018-08-27
NuGen–Tecan: investment, 201808 acquisition $54.5m in cash by Tecan 2018-08-16
Oncologie–Mologen: lefitolimod, 201808–201811 term sheet for acquisition of ww rights to lefitolimod by Oncologie TERMINATED 11/18 2018-08-15
United Kingdom (govt)–Bruker Corp: NMR technology, 201808 supply £20m NMR technology to 8 UK universities funded by EPSRC + BBSRC + MRC +NERC 2018-08-06
Foundation Medicine–Roche: investment, 201806–201807 acquisition all remaining shares for $2.4b in cash at $137/share 2018-06-19
Sanofi–Evotec: investment, 201806–201807 acquisition integration of Sanofi’s infectious disease RnD in Lyon into Evotec 2018-06-15
Andrew Alliance–SEVERAL: investment, 201806 financing round Series C $14m incl Tecan + Waters + Inpeco + Rancilio Cube + Sam Eletr + Omega Funds 2018-06-12
Andrew Alliance–Tecan: investment, 201806 financing round Series C totalling $14m incl Tecan Group 2018-06-12
Roche–Microbiotica: microbiomics, 201806– collab multi-year up to $534m r+d + commerc of markers + targets + treatments for IBD w Genentech 2018-06-06
Roivant–Oxford BioMedica: Parkinson’s gene therapy, 201806– license ww excl to OXB-102 $30m upfront + $812.5m milestones to Axovant Sciences 2018-06-06
Gilead–Hookipa: therapeutic vaccine technology, 201806– collab + license $10m upfront r+d immunotherapies against HIV + HBV 2018-06-05
Evotec–I’rom Group: iPSC technology, 201805– license non-excl for iPSCs produced with Sendai virus vector technology from ID Pharma 2018-05-23
Bluebird Bio–Medigene: TCR technology, 201805– collab strategic alliance expansion incl $8m one-time payment 2018-05-14
Armo BioSciences–Lilly: investment, 201805– acquisition $1.6b cash tender offer at $50/share by Eli Lilly 2018-05-10
InflaRx–SEVERAL: investment, 201805 primary public offering $51m+$7.65m w 1.5m+225k common shares at $34/share 2018-05-02
Crescendo Biologics–SEVERAL: investment, 201805 financing round Series B €57m led by Andera Partners 2018-04-30
Novartis–Pear Therapeutics: digital health, 201804– collab developm + commercialisation of prescripition digital therapeutics for drug abuse Sandoz 2018-04-18
Knauer–Microsaic: mass spectrometry, 201804– collab integration of Microsaic’s compact MS techn in Knauer’s LC platform 2018-04-12
Roivant–Arbutus Biopharma: RNA drugs, 201804– collab founding of jv Genevant Sciences to develop RNA drugs using LNP technology 2018-04-11
AveXis–Novartis: investment, 201804–201805 acquisition $8.7b in cash of AveXis Inc by Novartis for $128/share 2018-04-09
Polyphor–SEVERAL: investment, 201804–201805 IPO CHF155m (€130m) at SIX Swiss Exchange at CHF38/share 2018-04-09
Boehringer–OSE Immunotherapeutics: antibody cancer drug, 201804– collab + license ww OSE-172 €30m upfront+short-term + €1.1b milestones + royalties 2018-04-04
LCF Rothschild–Andera Partners: investment, 201804 management buy-out of EdRIP by employees + renaming to Andera Partners 2018-04-04
Novartis–GSK: investment, 201803– acquisition $13b of 36.5% stake of Novartis in OTC joint venture giving GSK 100% ownership 2018-03-27
NMD Pharma–SEVERAL: investment, 201803 financing round Series A €38m led by new investor Inkef Capital + incl RVF + Novo Seeds + Lundbeckfonden 2018-03-23
MorphoSys–SEVERAL: investment, 201803–201804 US IPO $208m+$31m with 8.3m+1.245m ADSs at $25.04/ADS + listing at Nasdaq Global Market 2018-03-22
Novartis–Harvard Univ: drug delivery technology, 201803– collab develop biomaterial systems for delivery of cancer immuntherapies NIBR + Wyss + Dana 2018-03-20
Prexton Therapeutics–Lundbeck: investment, 201803– acquisition €100m upfront + €805m developm + sales milestones ANNOUNCED 2018-03-16
Siemens–SEVERAL: investment, 201803 IPO €4.2b of Siemens Healthineers AG at FSE floating 150m (15% of) shares at €28/share 2018-03-16
Atomwise–SEVERAL: investment, 201803 financing round Series A $45m co-led by Monsanto GV + DCVC (Data Collective) + B Capital Group 2018-03-07
Magenta Therapeutics–Heidelberg Pharma: antibody-drug conjugates, 201803– collab developm of ADCs for bone marrow transplant using ATAC platform 2018-03-05
Aimmune Therapeutics–SEVERAL: investment, 201802–201803 public offering $176m+$26.4m net $190m with 5.5m+825k shares common stock at $32/share 2018-02-20
Addex–SEVERAL: investment, 201802–201803 private placement CHF40m with 12.78m new shares at CHF3.13/share plus 0.4 warrants at CHF3.43 2018-02-15
Flatiron Health–Roche: investment, 201802–201804 acquisition $1.9b of remaining 87.4% not already owned by Roche 2018-02-15
Pieris–SEVERAL: investment, 201802 public offering $50.6m with 5.5m+825k common shares at $8/share 2018-02-13
Affimed–SEVERAL: investment, 201802 public offering $26.5m ($24.5m net) with 12.5m+1.725m common shares at $2/share 2018-02-12
Seattle Genetics–Pieris: cancer immunotherapy, 201802– collab $30m upfront + $1.2b milestones + royalties developm antibody-anticalin fusion proteins 2018-02-09
Servier–ImmunoQure: therapeutic antibodies, 201802– collab developm of INF-alpha human autoantibody for autoimmune diseases 2018-02-06
STAT-Diagnostica–Qiagen: investment, 201801 acquisition $147m upfront cash + $44m milestones of STAT-Dx by Qiagen 2018-01-31
Ablynx–Sanofi: investment, 201801–201806 acquisition recommended cash tender offer €3.9b with €45/share 2018-01-29
Novartis–Spark Therapeutics: voretigene neparvovec, 201801– license ww outside US to develop + register + commerc gene therapy Luxtarna 2018-01-24
High-Tech Gründerfonds–Dräger: investment, 201801 investment of Dräger in HTGF III Fund 2018-01-23
Juno Therapeutics–Celgene: investment, 201801–201803 acquisition cash tender offer $9b net of cash + shares already owned by Celgene $87/share 2018-01-22
Novartis–Biocon: biosimilars, 201801– collab strategic ww excl developm + production + comercialisation Sandoz + Biocon 2018-01-18
Intelligent Pharma–Mind the Byte: investment, 201801 acquisition €na 100% of Intelligent Pharma by Mind the Byte 2018-01-11
Structural Genomics Consortium–Enamine: chemical compound libraries, 201801– supply new generation of Diamond-SGC-iNEXT (DSI) Poised Library 2018-01-10
General Electric–Roche: diagnostics, 201801– collab developm integrated digital + IVD + in vivo diagnostics platform for oncology + critical care 2018-01-08
TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share 2018-01-05
CureVac–Arcturus Therapeutics: mRNA therapeutics, 201801– strategic collab for lipid-mediated mRNA drugs using RNAoptimizer + LUNAR system 2018-01-04
CRISPR Therapeutics–SEVERAL: investment, 201801 public offering $113.75m of 5m+750k common shares at $22.75/share 2018-01-03
Ignyta–Roche: investment, 201712– cash tender offer $1.7b for all outstanding shares at $27/share 2017-12-21
Roche–Idorsia: cancer immunotherapy, 201712– collab research + excl license option €15m upfront + €445m milestones plus sales milestones + royalties 2017-12-20
Boehringer–Autifony: CNS drugs, 201712– collab €25m upfront + up to total of €627.5m excl option to acquire KV3.1/3.2 positive modulators for BI 2017-12-18
NorthSea Therapeutics–SEVERAL: investment, 201712 financing round Series A €25m co-led by Forbion + BGV + incl Novo Seeds + New Science Ventures 2017-12-12
Aelin Therapeutics–SEVERAL: investment, 201712 financing round Series A €27m from LSP + PMV + Novartis Venture Fund + BIVF + Fund+ 2017-12-11
JnJ–Idorsia: aprocitentan, 201712– collab developm + license ww commerc for Janssen $230m upfront + royalties 20–35% 2017-12-04
I-Mab–MorphoSys: antibody cancer drug, 201711– license excl Greater China for MOR202 with $20m upfront + $100m milestones + tiered 2-digit royalties 2017-11-30
Viewics–Roche: investment, 201711 acquisition of Viewics Inc by Roche 2017-11-17
Roche–Arvinas: protein degradation drugs, 201711– strategic license expansion for PROTAC technology to Genentech 2017-11-15
Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al 2017-11-15
Bayer–Loxo Oncology: TRK inhibitors, 201711– ww collab $400m upfront + $650m milestones developm of larotectinib + LOXO-195 2017-11-14
CRISPR Therapeutics–CureVac: mRNA technology, 201711– collab + license using RNArt techn to develop in-vivo gene-editing programs in liver diseases 2017-11-13
InflaRx–SEVERAL: investment, 201711 IPO $100m w 6.667m common shares at $15/share at Nasdaq Global Select Market 2017-11-10
Boehringer–MiNA Therapeutics: RNAa drugs, 201711– collab up to €307m plus royalties developm of RNAa drugs for fibrotic liver diseases incl NASH 2017-11-08
NousCom–SEVERAL: investment, 201711 financing round Series B €42m led by new investor Abingworth + incl 5AM Ventures + LSP + Versant Ventures 2017-11-06
Advanced Accelerator Applications–Novartis: investment, 201710–201801 cash tender offer $3.9b with $41/ordinary share 2017-10-30
Lilly–CureVac: cancer vaccines, 201710– collab ww $50m upfront + $45m equity investment + $1.7b milestones up to 5 products using RNActive technology 2017-10-18
SurgVision–Bracco: investment, 201710 acquisition of SurgVision BV by Bracco Imaging SpA 2017-10-18
Roche–Warp Drive Bio: drug discovery, 201710– strategic collab up to $387m plus royalties r+d of novel antibiotics using Genome Mining platform 2017-10-16
Kohlberg Kravis Roberts–Eurofins: investment, 201710– acquisition of LGC Forensics division of LGC Group from KKR 2017-10-12
Nestlé–Codexis: therapeutic enzymes, 201710– collab strategic alliance using CodeEvolver platform + incl option for ww developm of CDX-6114 2017-10-12
Exscientia–Evotec: investment, 201709 investment €15m by Evotec AG to acquire minority stake in Exscientia Ltd 2017-09-28
Novartis–Univ California: drug discovery technology, 201709– collab establishment of Novartis-Berkeley Center for Proteomics & Chemistry Technologies 2017-09-28
Humabs BioMed–Vir Biotechnology: investment, 201709 acquisition of Humabs by Vir 2017-09-21
Juno Therapeutics–SEVERAL: investment, 201709 public offering $250.1m+$37.515m with 6.1m+915k shares at $41/share 2017-09-20
Axiogenesis–Pluriomics: investment, 201709 merger into Ncardia 2017-09-18
1 2 3 4  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top